{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-003908","form_type":"8-K","ticker":"HYPD","cik":"0001682639","company_name":"HYPERION DEFI, INC.","filed_at":"2024-01-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.103273+00:00","generated_at":"2026-06-06T23:17:58.736536+00:00","sec_items":["1.01","1.02","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Eyenovia reacquires MicroPine rights from B&L for $2M cash + $3M stock","bullets":["Reacquired U.S. and Canada rights to MicroPine (late-phase III pediatric progressive myopia) from Bausch + Lomb Ireland.","Consideration: $2M upfront cash + $3M in common stock + low single-digit royalty on net sales in U.S./Canada.","MicroPine uses Optejet dispenser; market estimated at ~$2B annually in the U.S. by Review of Myopia Management.","Ongoing CHAPERONE trial to be transferred; Eyenovia plans to meet with FDA to explore expedited development path.","No impact on partnership with Arctic Vision covering Greater China and South Korea."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-003908","json":"https://secwatch.observer/filing/0001104659-24-003908.json","markdown":"https://secwatch.observer/filing/0001104659-24-003908.md","text":"https://secwatch.observer/filing/0001104659-24-003908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682639/000110465924003908/0001104659-24-003908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682639/000110465924003908/tm243285d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T23:17:58.736536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5a2b765fbd31d99ef6187958572d76e5f3448401","claim":"HYPERION DEFI, INC. entered into Letter Agreement with Bausch + Lomb Ireland Limited valued at cash and common stock consideration; $2 million upfront cash payment; $3 million in common stock; lo (effective 2024-01-12).","evidence_excerpt":"On January 12, 2024, after successful negotiations between Eyenovia and B&L regarding the pediatric progressive myopia program, B&L and Eyenovia entered into a Letter Agreement (the “Letter Agreement”), pursuant to which Eyenovia will reacquire the rights to this program.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1682639/000110465924003908/0001104659-24-003908-index.htm","confidence":0.92,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Bausch + Lomb Ireland Limited"},{"label":"Value","value":"cash and common stock consideration; $2 million upfront cash payment; $3 million in common stock; lo"},{"label":"Effective","value":"2024-01-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}